文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

包含逆转录病毒蛋白酶可增强针对HIV-1或SARS-CoV-2的形成病毒样颗粒的mRNA疫苗在小鼠中的免疫原性。

Inclusion of a retroviral protease enhances the immunogenicity of VLP-forming mRNA vaccines against HIV-1 or SARS-CoV-2 in mice.

作者信息

Zhang Peng, Singh Mamta, Becker Vada A, Croft Jacob, Tsybovsky Yaroslav, Gopan Vinay, Seo Yuna, Liu Qingbo, Rogers Denise, Miao Huiyi, Lin Yin, Rogan Daniel, Shields Courtney, Elbashir Sayda M, Calabrese Samantha, Renzi Isabella, Preznyak Vladimir, Narayanan Elizabeth, Stewart-Jones Guillaume, Himansu Sunny, Connors Mark, Lee Kelly, Carfi Andrea, Lusso Paolo

机构信息

Laboratory of Immunoregulation and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.

Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195, USA.

出版信息

Sci Transl Med. 2025 Apr 30;17(796):eadt9576. doi: 10.1126/scitranslmed.adt9576.

DOI:10.1126/scitranslmed.adt9576
PMID:40305570
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12151460/
Abstract

Messenger RNA (mRNA) has emerged as a highly effective and versatile platform for vaccine delivery. We previously designed a virus-like particle (VLP)-forming mRNA vaccine against human immunodeficiency virus-1 (HIV-1) that elicited envelope-specific neutralizing antibodies and protection from heterologous simian-human immunodeficiency virus (SHIV) infection in rhesus macaques. Here, we introduce a key technological advance to this platform by inclusion of mRNA encoding a retroviral protease to process Gag and produce mature VLPs. Appropriately dosed and timed expression of the protease was achieved using a full-length mRNA transcript. Addition of mRNA to an HIV-1 mRNA vaccine resulted in enhanced titers of envelope trimer-binding and neutralizing antibodies in a mouse model. Analogous results were obtained with a hybrid Gag-based, VLP-forming severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine expressing an engineered spike protein. Thus, inclusion of a retroviral protease can increase the immunogenicity of Gag-based, VLP-forming mRNA vaccines against human pathogens.

摘要

信使核糖核酸（mRNA）已成为一种高效且通用的疫苗递送平台。我们之前设计了一种针对人类免疫缺陷病毒1型（HIV-1）的形成病毒样颗粒（VLP）的mRNA疫苗，该疫苗能在恒河猴体内引发包膜特异性中和抗体，并提供针对异源猴-人免疫缺陷病毒（SHIV）感染的保护。在此，我们通过纳入编码逆转录病毒蛋白酶以加工Gag并产生成熟VLP，为该平台引入了一项关键技术进展。使用全长mRNA转录本实现了蛋白酶的适当剂量和适时表达。在小鼠模型中，向HIV-1 mRNA疫苗中添加mRNA导致包膜三聚体结合抗体和中和抗体滴度升高。对于表达工程化刺突蛋白的基于Gag的形成VLP的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）杂交mRNA疫苗，也获得了类似结果。因此，纳入逆转录病毒蛋白酶可增强针对人类病原体的基于Gag的形成VLP的mRNA疫苗的免疫原性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/7a7553b38bbe/nihms-2079224-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/c02cb6029791/nihms-2079224-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/3530d76fca7f/nihms-2079224-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/2879e3a8850b/nihms-2079224-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/135e95337823/nihms-2079224-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/5d8c122c5f3c/nihms-2079224-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/f5c2422476d7/nihms-2079224-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/01b281409a34/nihms-2079224-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/7a7553b38bbe/nihms-2079224-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/c02cb6029791/nihms-2079224-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/3530d76fca7f/nihms-2079224-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/2879e3a8850b/nihms-2079224-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/135e95337823/nihms-2079224-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/5d8c122c5f3c/nihms-2079224-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/f5c2422476d7/nihms-2079224-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/01b281409a34/nihms-2079224-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcfd/12151460/7a7553b38bbe/nihms-2079224-f0008.jpg

相似文献

[1]
Inclusion of a retroviral protease enhances the immunogenicity of VLP-forming mRNA vaccines against HIV-1 or SARS-CoV-2 in mice.

Sci Transl Med. 2025-4-30

[2]
Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam.

Microbiol Spectr. 2024-8-6

[3]
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.

Nat Med. 2021-12

[4]
A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.

Viruses. 2019-2-16

[5]
Development and Evaluation of a Newcastle Disease Virus-like Particle Vaccine Expressing SARS-CoV-2 Spike Protein with Protease-Resistant and Stability-Enhanced Modifications.

Viruses. 2024-12-18

[6]
Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.

J Virol. 2024-9-17

[7]
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection.

Sci Rep. 2024-11-9

[8]
Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles.

Proc Natl Acad Sci U S A. 2023-7-18

[9]
A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice.

Emerg Microbes Infect. 2024-12

[10]
Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.

Vaccine. 2016-10-17

引用本文的文献

[1]
Enhanced HIV-1 Neutralizing Antibody Breadth in HTLV-2 Co-Infected Individuals: Influence of Antiretroviral Regimen and B Cell Subset Distribution.

Vaccines (Basel). 2025-6-13

本文引用的文献

[1]
FDA approves mRNA-based RSV vaccine.

Nat Rev Drug Discov. 2024-7

[2]
Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice.

Sci Transl Med. 2024-5-22

[3]
mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies.

Science. 2024-5-17

[4]
Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates.

Science. 2024-5-17

[5]
SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series.

Sci Rep. 2024-4-18

[6]
Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques.

Cell. 2024-1-4

[7]
Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques.

Nat Commun. 2023-8-8

[8]
Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles.

Proc Natl Acad Sci U S A. 2023-7-18

[9]
Vaccination induces HIV broadly neutralizing antibody precursors in humans.

Science. 2022-12-2

[10]
Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants.

Cell Rep. 2022-11-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索